François Jornayvaz

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


81 publications

2023 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003 |
2023
 
Traitement du diabète de type 2 : et si nous revenions à l’essentiel ?
Jornayvaz F.R., Wojtusciszyn A., 2023/05/31. Revue medicale suisse, 19 (829) pp. 1063-1064. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_4F0B495469A1]
2018
 
Diabète de type 1, activité physique et nouvelles technologies [Type 1 diabetes, physical activity and novel technology]
Kosinski C., Le Dizès O., Gastaldi G., Andrey M., Amati F., Jornayvaz F.R., Puder J.J., 2018/05/30. Revue medicale suisse, 14 (609) pp. 1139-1144. Peer-reviewed.
[Pmid][serval:BIB_15BA3E62346F]
2017
AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient mice.
Carneiro L., Asrih M., Repond C., Sempoux C., Stehle J.C., Leloup C., Jornayvaz F.R., Pellerin L., 2017/12. Molecular metabolism, 6 (12) pp. 1625-1633. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1E26E53BF1FE]
 
Grip strength is not associated with incident type 2 diabetes mellitus in healthy adults: The CoLaus study.
Marques-Vidal P., Vollenweider P., Waeber G., Jornayvaz F.R., 2017/10. Diabetes research and clinical practice, 132 pp. 144-148. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EDB599430EB1]
 
Diabète sucré secondaire à une endocrinopathie : quand y penser ? [Diabetes mellitus secondary to an endocrine pathology : when to think about it ?]
Rouiller N., Jornayvaz F.R., 2017/05/31. Revue medicale suisse, 13 (565) pp. 1158-1162. Peer-reviewed.
[Pmid][serval:BIB_540E98E43238]
 
Diètes cétogènes : la solution miracle ? [Ketogenic diets : the miraculous solution ?]
Kosinski C., Jornayvaz F.R., 2017/05/31. Revue medicale suisse, 13 (565) pp. 1145-1147. Peer-reviewed.
[Pmid][serval:BIB_908A4366C89B]
 
Utilité de la mesure en continu de la glycémie chez les patients diabétiques de type 2 [Value of continuous glucose monitoring in type 2 diabetic patients]
Corcillo A., Girardin S., Andrey M., Le Dizès O., Jornayvaz F.R., 2017/05/31. Revue medicale suisse, 13 (565) pp. 1140-1144. Peer-reviewed.
[Pmid][serval:BIB_2EDC86ADDC06]
Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies.
Kosinski C., Jornayvaz F.R., 2017/05/19. Nutrients, 9 (5) p. 0. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_215D122FF452]
Treatment challenges in type 1 diabetes after roux-en-Y gastric bypass.
Favre L., Pralong F., Suter M., Jornayvaz F.R., 2017/03/21. Swiss medical weekly, 147 pp. w14420. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9393C45FD2C5]
 
GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on bone.
Philippe C., Wauquier F., Landrier J.F., Bonnet L., Miot-Noirault E., Rochefort G.Y., Sadoine J., Asrih M., Jornayvaz F.R., Bernalier A. et al., 2017/02. Molecular nutrition & food research, 61 (2) p. 10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_306588060812]
 
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid.
Schaffer C., Buclin T., Jornayvaz F.R., Cazzaniga S., Borradori L., Gilliet M., Feldmeyer L., 2017. Dermatology, 233 (5) pp. 401-403. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F51570C10D05]
2016
 
Sécurité cardiovasculaire des antidiabétiques [Cardiovascular safety of antidiabetics]
Aline Roth P.W., Jornayvaz F.R., 2016/06/01. Revue medicale suisse, 12 (521) pp. 1084,1086-1088. Peer-reviewed.
[Pmid][serval:BIB_352459C4E3D5]
Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study.
Jornayvaz F.R., Vollenweider P., Bochud M., Mooser V., Waeber G., Marques-Vidal P., 2016/05/03. Cardiovascular diabetology, 15 p. 73. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_294E477D2C7F]
 
Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance.
Popov V.B., Jornayvaz F.R., Akgul E.O., Kanda S., Jurczak M.J., Zhang D., Abudukadier A., Majumdar S.K., Guigni B., Petersen K.F. et al., 2016/03. FASEB journal, 30 (3) pp. 1207-1217. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ABD2A6CEFD64]
 
Comment faire pour prévenir le diabète de type 2 en Suisse
Philippe J., Jornayvaz F.R., 2016. Revue Médicale Suisse, 12 (521) pp. 1075-1076. Peer-reviewed.
[Pmid][serval:BIB_080F73559559]
 
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection.
Brinck J.W., Thomas A., Lauer E., Jornayvaz F.R., Brulhart-Meynet M.C., Prost J.C., Pataky Z., Löfgren P., Hoffstedt J., Eriksson M. et al., 2016. Arteriosclerosis, Thrombosis, and Vascular Biology, 36 (5) pp. 817-824. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_71CA238E953E]
Diabète gestationnel--quelles sont les approches non médicales [Gestational diabetes--what are the non-medical approaches?].
Horsch A., Gross J., Jornayvaz F.R., Lanzi S., Puder J.J., 2016. Revue Médicale Suisse, 12 (521) pp. 1089-1091. Peer-reviewed.
[URN][Pmid][serval:BIB_6A11F7942EAD]
 
Diabétologie [News in diabetology 2015].
Jornayvaz F.R., 2016. Revue Médicale Suisse, 12 (500) pp. 30-31. Peer-reviewed.
[Pmid][serval:BIB_3570FAAD7401]
Leptin as a Potential Regulator of FGF21.
Asrih M., Veyrat-Durebex C., Poher A.L., Lyautey J., Rohner-Jeanrenaud F., Jornayvaz F.R., 2016. Cellular Physiology and Biochemistry, 38 (3) pp. 1218-1225. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5AB6975674ED]
 
Place des nouveaux antidiabétiques dans la population gériatrique [Use of new antidiabetics in the elderly population].
Besse S., Besse A., Jornayvaz F.R., 2016. Revue Médicale Suisse, 12 (521) pp. 1101-1106. Peer-reviewed.
[Pmid][serval:BIB_F072D879DB14]
Preserving of Postnatal Leptin Signaling in Obesity-Resistant Lou/C Rats following a Perinatal High-Fat Diet.
Poher A.L., Arsenijevic D., Asrih M., Dulloo A.G., Jornayvaz F.R., Rohner-Jeanrenaud F., Veyrat-Durebex C., 2016. PloS one, 11 (9) pp. e0162517. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E10F9E8A8E4C]
2015
 
ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content.
Camporez J.P., Kanda S., Petersen M.C., Jornayvaz F.R., Samuel V.T., Bhanot S., Petersen K.F., Jurczak M.J., Shulman G.I., 2015. Journal of Lipid Research, 56 (3) pp. 526-536. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_16C644C971F5]
 
Classification du diabète: vers une hétérogénéité croissante [Classification of diabetes: an increasing heterogeneity].
Vionnet A.C., Jornayvaz F.R., 2015. Revue Médicale Suisse, 11 (477) pp. 1234-1237.
[Pmid][serval:BIB_7E5C4BB5333F]
 
Edulcorants artificiels et diabète: faux amis [Artificial sweeteners and diabetes: friends or foes?].
Tran C., Jornayvaz F.R., 2015. Revue Médicale Suisse, 11 (477) pp. 1246-1249.
[Pmid][serval:BIB_4775DB8C3A50]
 
Endocrine causes of nonalcoholic fatty liver disease.
Marino L., Jornayvaz F.R., 2015. World Journal of Gastroenterology, 21 (39) pp. 11053-11076. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9C084B4D0CBF]
 
Free Fatty Acids Impair FGF21 Action in HepG2 Cells.
Asrih M., Montessuit C., Philippe J., Jornayvaz F.R., 2015. Cellular Physiology and Biochemistry, 37 (5) pp. 1767-1778. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_461A22BDA986]
 
Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21.
Camporez J.P., Asrih M., Zhang D., Kahn M., Samuel V.T., Jurczak M.J., Jornayvaz F.R., 2015. Journal of Endocrinology, 226 (3) pp. 207-217. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F362F4CAC80C]
 
Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue.
Asrih M., Altirriba J., Rohner-Jeanrenaud F., Jornayvaz F.R., 2015. PLoS One, 10 (5) pp. e0126364.
[DOI][WoS][Pmid][serval:BIB_397D49C7FEC6]
 
Le diabète en 2015: en augmentation constante, mais avec une offre thérapeutique qui s'élargit [Diabetes in 2015: constantly increasing, but with enlarged therapeutics options].
Jornayvaz F.R., Philippe J., 2015. Revue Médicale Suisse, 11 (477) pp. 1219-1220.
[Pmid][serval:BIB_22CC052FC5FF]
 
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M., Jornayvaz F.R., 2015. Molecular and Cellular Endocrinology, 418 Pt 1 pp. 55-65. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_88D1022A93C0]
 
Metformine: nouvelles données pour une ancienne molecule [Metformin: new data for an old molecule].
Sanduloviciu M., Jornayvaz F.R., 2015. Revue Médicale Suisse, 11 (477) pp. 1222-1226.
[Pmid][serval:BIB_3743779B7147]
 
Prise en charge des facteurs de risque des maladies cardiovasculaires: qu'est-ce qui a vraiment changé en 15 ans [Management of cardiovascular diseases in adults from 1999 to 2014: what has really changed?].
Barthel C., Nanchen D., Jornayvaz F.R., Wuerzner G., Senn N., 2015. Revue Médicale Suisse, 11 (496) pp. 2228, 2230-2228, 2235. Peer-reviewed.
[Pmid][serval:BIB_00C3BE9BD61E]
 
Serum Vitamin D Concentrations Are Not Associated with Insulin Resistance in Swiss Adults.
Marques-Vidal P., Vollenweider P., Guessous I., Henry H., Boulat O., Waeber G., Jornayvaz F.R., 2015. Journal of Nutrition, 145 (9) pp. 2117-2122. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2F4D988BC74E]
 
Transition en diabétologie [Transition in diabetology].
Hauschild M., Elowe-Gruau E., Dwyer A., Aquarone M.P., Unal S., Jornayvaz F.R., Perrenoud L., Gastaldi G., Castellsague M., Dirlewanger M. et al., 2015. Revue Médicale Suisse, 11 (462) pp. 450-2, 454-5.
[Pmid][serval:BIB_E2BECF473AA3]
2014
 
Capsule commentary on Patrick et al., trends in insulin initiation and treatment intensification among patients with type 2 diabetes.
Jornayvaz F.R., 2014. Journal of General Internal Medicine, 29 (2) p. 356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_477E49484B75]
 
Diets and nonalcoholic fatty liver disease: the good and the bad.
Asrih M., Jornayvaz F.R., 2014. Clinical Nutrition, 33 (2) pp. 186-190. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_538BA4088928]
 
Maladies hépatiques chroniques et diabète [Chronic liver diseases and diabetes].
Jaafar J., de Kalbermatten B., Philippe J., Scheen A., Jornayvaz F.R., 2014. Revue Médicale Suisse, 10 (433) pp. 1254, 1256-1254, 1260.
[Pmid][serval:BIB_BF005E0439A9]
 
Muscle-specific activation of Ca(2+)/calmodulin-dependent protein kinase IV increases whole-body insulin action in mice.
Lee H.Y., Gattu A.K., Camporez J.P., Kanda S., Guigni B., Kahn M., Zhang D., Galbo T., Birkenfeld A.L., Jornayvaz F.R. et al., 2014. Diabetologia, 57 (6) pp. 1232-1241. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ADB09C6AF6EE]
 
Ostα-/- mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivity.
Wheeler S.G., Hammond C.L., Jornayvaz F.R., Samuel V.T., Shulman G.I., Soroka C.J., Boyer J.L., Hinkle P.M., Ballatori N., 2014. American Journal of Physiology. Gastrointestinal and Liver Physiology, 306 (5) pp. G425-G438. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1A607B7DBDFF]
 
Traitement combiné d'insuline et d'analogue du GLP-1: qu'en attendre [Combined treatment of insulin and GLP-1 analogs: what do we expect?].
de Kalbermatten B., Jaafar J., Jornayvaz F.R., Philippe J., 2014. Revue Médicale Suisse, 10 (433) pp. 1235-6, 1238-40.
[Pmid][serval:BIB_698E4ADC87DC]
2013
 
Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance.
Camporez J.P., Jornayvaz F.R., Lee H.Y., Kanda S., Guigni B.A., Kahn M., Samuel V.T., Carvalho C.R., Petersen K.F., Jurczak M.J. et al., 2013. Endocrinology, 154 (3) pp. 1021-1028. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8821C1141F35]
 
Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice.
Camporez J.P., Jornayvaz F.R., Petersen M.C., Pesta D., Guigni B.A., Serr J., Zhang D., Kahn M., Samuel V.T., Jurczak M.J. et al., 2013. Endocrinology, 154 (9) pp. 3099-3109. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3D927EE23D2B]
 
CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance.
Cantley J.L., Yoshimura T., Camporez J.P., Zhang D., Jornayvaz F.R., Kumashiro N., Guebre-Egziabher F., Jurczak M.J., Kahn M., Guigni B.A. et al., 2013. Proceedings of the National Academy of Sciences of the United States of America, 110 (5) pp. 1869-1874. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_22209C120A1B]
 
Enhanced fasting glucose turnover in mice with disrupted action of TUG protein in skeletal muscle.
Löffler M.G., Birkenfeld A.L., Philbrick K.M., Belman J.P., Habtemichael E.N., Booth C.J., Castorena C.M., Choi C.S., Jornayvaz F.R., Gassaway B.M. et al., 2013. Journal of Biological Chemistry, 288 (28) pp. 20135-20150. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9D31A168702D]
 
Increased FGF21 plasma levels in humans with sepsis and SIRS.
Gariani K., Drifte G., Dunn-Siegrist I., Pugin J., Jornayvaz F.R., 2013. Endocrine Connections, 2 (3) pp. 146-153. Peer-reviewed.
[DOI][Pmid][serval:BIB_35E007E184CA]
 
Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance.
Asrih M., Jornayvaz F.R., 2013. Journal of Endocrinology, 218 (3) pp. R25-R36. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_309FD7C8EC75]
 
Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside.
Gariani K., Philippe J., Jornayvaz F.R., 2013. Diabetes and Metabolism, 39 (1) pp. 16-26. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E113952542A]
 
Sport et diabète de type 1 [Sport and type 1 diabetes].
Büsser C., Meyer P., Philippe J., Jornayvaz F.R., 2013. Revue Médicale Suisse, 9 (389) pp. 1200, 1202-1200, 1205.
[Pmid][serval:BIB_BA454B05918B]
2012
 
A rare cause of hypertestosteronemia in a 68-year-old patient: a Leydig cell tumor due to a somatic GNAS (guanine nucleotide-binding protein, alpha-stimulating activity polypeptide 1)-activating mutation.
Libé R., Fratticci A., Lahlou N., Jornayvaz F.R., Tissier F., Louiset E., Guibourdenche J., Vieillefond A., Zerbib M., Bertherat J., 2012. Journal of Andrology, 33 (4) pp. 578-584.
[DOI][WoS][Pmid][serval:BIB_1AC106480FD0]
 
Development of insulin resistance in mice lacking PGC-1α in adipose tissues.
Kleiner S., Mepani R.J., Laznik D., Ye L., Jurczak M.J., Jornayvaz F.R., Estall J.L., Chatterjee Bhowmick D., Shulman G.I., Spiegelman B.M., 2012. Proceedings of the National Academy of Sciences of the United States of America, 109 (24) pp. 9635-9640. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5DCD7E6ACE8B]
 
Diabète et stéatose hépatique non alcoolique [Diabetes and non-alcoholic fatty liver disease].
Gariani K., Philippe J., Jornayvaz F.R., 2012. Revue Médicale Suisse, 8 (344) pp. 1211-1214. Peer-reviewed.
[Pmid][serval:BIB_D9E5AA56AD05]
 
Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance.
Jornayvaz F.R., Shulman G.I., 2012. Cell Metabolism, 15 (5) pp. 574-584. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1618479457A]
 
Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice.
Jurczak M.J., Lee A.H., Jornayvaz F.R., Lee H.Y., Birkenfeld A.L., Guigni B.A., Kahn M., Samuel V.T., Glimcher L.H., Shulman G.I., 2012. Journal of Biological Chemistry, 287 (4) pp. 2558-2567. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C0A825AFCA28]
 
Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients.
Gattu A.K., Birkenfeld A.L., Jornayvaz F., Dziura J., Li F., Crawford S.E., Chu X., Still C.D., Gerhard G.S., Chung C. et al., 2012. Acta Diabetologica, 49 (Suppl 1) pp. S161-S169. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_374082E15249]
 
Sommeil et diabéte [Sleep and diabetes].
Hernandez A., Philippe J., Jornayvaz F.R., 2012. Revue Médicale Suisse, 8 (344) pp. 1198-200, 1202-3.
[Pmid][serval:BIB_3EF734CB1ABA]
 
Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance.
Jornayvaz F.R., Lee H.Y., Jurczak M.J., Alves T.C., Guebre-Egziabher F., Guigni B.A., Zhang D., Samuel V.T., Silva J.E., Shulman G.I., 2012. Endocrinology, 153 (2) pp. 583-591. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E2983EE945F8]
 
Weight and mortality in adults with diabetes.
Jornayvaz F.R., 2012. Jama, 308 (20) pp. 2080; author reply 2080-2080; author reply 2081. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_947B539D35E5]
2011
 
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance.
Lee H.Y., Birkenfeld A.L., Jornayvaz F.R., Jurczak M.J., Kanda S., Popov V., Frederick D.W., Zhang D., Guigni B., Bharadwaj K.G. et al., 2011. Hepatology, 54 (5) pp. 1650-1660. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BC682719869]
 
Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice.
Birkenfeld A.L., Lee H.Y., Guebre-Egziabher F., Alves T.C., Jurczak M.J., Jornayvaz F.R., Zhang D., Hsiao J.J., Martin-Montalvo A., Fischer-Rosinsky A. et al., 2011. Cell Metabolism, 14 (2) pp. 184-195. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_21BAB299A947]
 
Diet, lifestyle, and long-term weight gain.
Jornayvaz F.R., 2011. New England Journal of Medicine, 365 (11) pp. 1058-9; author reply 1059. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_970644357413]
 
Fibroblast growth factor 21, ketogenic diets, and insulin resistance.
Jornayvaz F.R., 2011. American Journal of Clinical Nutrition, 94 (3) pp. 955; author reply 956-955; author reply 957.
[DOI][WoS][Pmid][serval:BIB_11410AAF646E]
 
Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2.
Jornayvaz F.R., Birkenfeld A.L., Jurczak M.J., Kanda S., Guigni B.A., Jiang D.C., Zhang D., Lee H.Y., Samuel V.T., Shulman G.I., 2011. Proceedings of the National Academy of Sciences of the United States of America, 108 (14) pp. 5748-5752. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_59EB0F96190A]
 
Influence of the hepatic eukaryotic initiation factor 2alpha (eIF2alpha) endoplasmic reticulum (ER) stress response pathway on insulin-mediated ER stress and hepatic and peripheral glucose metabolism.
Birkenfeld A.L., Lee H.Y., Majumdar S., Jurczak M.J., Camporez J.P., Jornayvaz F.R., Frederick D.W., Guigni B., Kahn M., Zhang D. et al., 2011. Journal of Biological Chemistry, 286 (42) pp. 36163-36170. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_71B0AA93E117]
 
Pregnancy does not accelerate corticotroph tumor progression in Nelson's syndrome.
Jornayvaz F.R., Assie G., Bienvenu-Perrard M., Coste J., Guignat L., Bertherat J., Silvera S., Bertagna X., Legmann P., 2011. Journal of Clinical Endocrinology and Metabolism, 96 (4) pp. E658-E662. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_74DAA6307DDA]
 
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
Jurczak M.J., Lee H.Y., Birkenfeld A.L., Jornayvaz F.R., Frederick D.W., Pongratz R.L., Zhao X., Moeckel G.W., Samuel V.T., Whaley J.M. et al., 2011. Diabetes, 60 (3) pp. 890-898.
[DOI][WoS][Pmid][serval:BIB_3D030338A6FB]
2010
 
A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain.
Jornayvaz F.R., Jurczak M.J., Lee H.Y., Birkenfeld A.L., Frederick D.W., Zhang D., Zhang X.M., Samuel V.T., Shulman G.I., 2010. American Journal of Physiology. Endocrinology and Metabolism, 299 (5) pp. E808-E815.
[DOI][WoS][Pmid][serval:BIB_6719E9817BA3]
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.
Zanchi A., Maillard M., Jornayvaz F.R., Vinciguerra M., Deleaval P., Nussberger J., Burnier M., Pechere-Bertschi A., 2010. Diabetologia, 53 (8) pp. 1568-1575.
[URN][DOI][WoS][Pmid][serval:BIB_2DCD23BF24A5]
 
Regulation of mitochondrial biogenesis.
Jornayvaz F.R., Shulman G.I., 2010. Essays in Biochemistry, 47 pp. 69-84.
[DOI][WoS][Pmid][serval:BIB_61DB56725866]
 
Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance.
Lee H.Y., Choi C.S., Birkenfeld A.L., Alves T.C., Jornayvaz F.R., Jurczak M.J., Zhang D., Woo D.K., Shadel G.S., Ladiges W. et al., 2010. Cell Metabolism, 12 (6) pp. 668-674.
[DOI][WoS][Pmid][serval:BIB_0AD8CF7C3E94]
 
The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.
Jornayvaz F.R., Samuel V.T., Shulman G.I., 2010. Annual Review of Nutrition, 30 pp. 273-290. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D424112340CB]
2009
 
Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.
Jornayvaz F.R., Brulhart-Meynet M.C., James R.W., 2009. Nutrition, Metabolism, and Cardiovascular Diseases, 19 (9) pp. 613-619. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8C7C88A4E63E]
2008
 
Mucocutaneous papillomatous papules in Cowden's syndrome.
Jornayvaz F.R., Philippe J., 2008. Clinical and Experimental Dermatology, 33 (2) pp. 151-153.
[DOI][WoS][Pmid][serval:BIB_4348B05AD7AC]
2007
 
Diabète sucré et conduite automobile [Diabetes mellitus and driving].
Jornayvaz F.R., Raguso C.A., Philippe J., 2007. Revue Médicale Suisse, 3 (114) pp. 1437-8, 1440-1.
[Pmid][serval:BIB_59D3785DFC54]
 
L'activité physique dans la prévention et le contrôle du diabète [Physical activity in the prevention and control of diabetes].
Raguso C.A., Spada A., Jornayvaz F.R., Philippe J., 2007. Revue Médicale Suisse, 3 (114) pp. 1442, 1445-1442, 1448.
[Pmid][serval:BIB_461154E2E974]
 
Le diabétique en attitude: physiopathologie et conséquences pratiques. [The diabetic patient at altitude: pathophysiology and practical implications]
Thalmann S., Gojanovic B., Jornayvaz F. R., Gremion G., Philippe J., 2007. Revue Médicale Suisse, 3 (114) pp. 1463-1466, 1468.
[Pmid][serval:BIB_26628ACDFEF7]
 
Traitements futurs de l'insulino-résistance [Insulin resistance treatments in the future].
Philippe J., Jornayvaz F., 2007. Journal de la Société de Biologie, 201 (2) pp. 155-158. Peer-reviewed.
[Pmid][serval:BIB_AAE1F1EF1031]
2006
 
Anticoagulants et cancer: au-delà de la prévention de la maladie thromboembolique [Anticoagulants and cancer: beyond thromboembolic disease prevention].
Jornayvaz F.R., Perrier A., 2006. Revue Médicale Suisse, 2 (83) pp. 2350-2353.
[Pmid][serval:BIB_E5F482EF7E1A]
2004
 
Assessment of hepatic glucose metabolism by indirect calorimetry in combination with a non-invasive technique using naturally enriched 13C glucose in healthy children and adolescents
Selz R., Jornayvaz F. R., Tappy L., Woringer V., Theintz G. E., 2004. Hormone Research, 62 (3) pp. 142-8.
[DOI][WoS][Pmid][serval:BIB_D0E5B0CCED08]
 
Metabolism of oral glucose in children born small for gestational age: evidence for an impaired whole body glucose oxidation.
Jornayvaz F.R., Selz R., Tappy L., Theintz G.E., 2004. Metabolism, 53 (7) pp. 847-851.
[DOI][WoS][Pmid][serval:BIB_FCCEF70EE7E2]
 
Stratégies diagnostiques des diarrhées chroniques de l'adulte [Chronic diarrhea in adults: diagnostic strategies]
Jornayvaz F.R., Michetti P., Rotman S., Waeber G., 2004. Praxis, 93 (50) pp. 2099-104.
[Pmid][serval:BIB_C8902804C62B]
2003
 
Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1.
Schwitzgebel V.M., Mamin A., Brun T., Ritz-Laser B., Zaiko M., Maret A., Jornayvaz F.R., Theintz G.E., Michielin O., Melloul D. et al., 2003. The Journal of clinical endocrinology and metabolism, 88 (9) pp. 4398-406. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0AC59D937E23]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University